What changed
Deals & ownershipRatnakar Lavu, executive vice president and chief digital information officer at Elevance Health, sold 1,300 company shares on November 5, 2026. The weighted average price for the transaction was $440 per share.

What changedElevance Health posted third-quarter 2026 operating revenue of $50.4 billion, up 0.7% from a year earlier, and raised its full-year outlook. The company now expects adjusted earnings per share of at least $29.00.

Upcoming events
As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →
Company history
October 2026
Elevance Health, Inc.: 12 recorded developments from 1 official source in 2026-10.
- 2026-10-21: Revenue (us-gaap:Revenues), quarter 2026-07-01 to 2026-09-30: 51,429,000,000 USD (51.4 billion; 51,429 million); same period a year earlier (2025-07-01 to 2025-09-30): 50,711,000,000 USD (50.7 billion; 50,711 million); change +1.4% Source
- 2026-10-21: Revenue (us-gaap:Revenues), year to date 2026-01-01 to 2026-09-30: 152,084,000,000 USD (152.1 billion; 152,084 million); same period a year earlier (2025-01-01 to 2025-09-30): 149,378,000,000 USD (149.4 billion; 149,378 million); change +1.8% Source
- 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 1,269,000,000 USD (1.3 billion; 1,269 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,295,000,000 USD (1.3 billion; 1,295 million); change -2% Source
- 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 5,118,000,000 USD (5.1 billion; 5,118 million); same period a year earlier (2025-01-01 to 2025-09-30): 6,890,000,000 USD (6.9 billion; 6,890 million); change -25.7% Source
- 2026-10-21: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 1,365,000,000 USD (1.4 billion; 1,365 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,189,000,000 USD (1.2 billion; 1,189 million); change +14.8% Source
- 2026-10-21: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 4,592,000,000 USD (4.6 billion; 4,592 million); same period a year earlier (2025-01-01 to 2025-09-30): 5,115,000,000 USD (5.1 billion; 5,115 million); change -10.2% Source
- 2026-10-21: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 7,512,000,000 USD (7.5 billion; 7,512 million); same period a year earlier (2025-01-01 to 2025-09-30): 4,206,000,000 USD (4.2 billion; 4,206 million); change +78.6% Source
- 2026-10-21: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-30: 789,000,000 USD (789 million); same period a year earlier (2025-01-01 to 2025-09-30): 823,000,000 USD (823 million); change -4.1% Source
- 2026-10-21: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 10,348,000,000 USD (10.3 billion; 10,348 million); previous balance (2025-12-31): 9,491,000,000 USD (9.5 billion; 9,491 million); change +9% Source
- 2026-10-21: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 83,007,000,000 USD (83 billion; 83,007 million); previous balance (2025-12-31): 77,468,000,000 USD (77.5 billion; 77,468 million); change +7.2% Source
- 2026-10-21: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 44,681,000,000 USD (44.7 billion; 44,681 million); previous balance (2025-12-31): 43,882,000,000 USD (43.9 billion; 43,882 million); change +1.8% Source
- 2026-10-21: Long-term debt (us-gaap:LongTermDebtNoncurrent), as of 2026-09-30: 30,382,000,000 USD (30.4 billion; 30,382 million); previous balance (2025-12-31): 30,797,000,000 USD (30.8 billion; 30,797 million); change -1.3% Source
July 2026
Elevance Health reported on medical membership, market-driven medical cost trends, and operational impacts of regulatory changes in its July 2026 filing.
- As of June 30, 2026, Elevance Health served approximately 44.9 million medical members through its affiliated health plans. Source
- The company reported that membership shifts from Medicaid to the Individual ACA business combined with lower effectuation rates have driven a market-wide increase in morbidity and elevated medical cost trends. Source
- Medicaid cost trends remain elevated due to higher population acuity and increased utilization of services. Source
- Elevance Health participated in the Public Exchange and expanded operations into Florida, Maryland, Texas, and Washington between 2025 and 2026. Source
- CarelonRx continues to delegate certain pharmacy services to CVS Health Corporation's subsidiary CaremarkPCS Health, L.L.C. under an agreement through December 31, 2027. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
Company officers will reaffirm full year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.
Said November 10, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
Company officers will reaffirm the Company’s shareholders’ earnings guidance for full year 2026 to be at least $22.00 per diluted share, including approximately $7.00 per diluted share of net unfavorable items.
Said November 10, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
Elevance Health expects FY 2026 adjusted diluted EPS of at least $29.00.
Said October 21, 2026 · Period named: FY 2026 · Source · Our article
Not yet checked against later reports.
The CEO expects at least 12% growth in adjusted diluted EPS in 2027 from a baseline of at least $26.75.
Said October 21, 2026 · Period named: 2027 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 19,523,886 | $7,591,277,244 | +2.8% | Q3 2026 |
| State Street | 10,493,831 | $4,080,211,369 | +0.6% | Q3 2026 |
| Wellington Management | 8,516,420 | $3,311,354,424 | -7.6% | Q3 2026 |
| Geode Capital Management | 5,216,506 | $2,019,246,207 | +1.0% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 3,958,856 | $1,531,008,381 | — | Q2 2026 |
| Fidelity (FMR) | 2,370,165 | $921,567,674 | -24.3% | Q3 2026 |
| Citadel Advisors | 388,335 | $150,992,414 | -57.2% | Q3 2026 |
| Renaissance Technologies | 322,613 | $125,438,387 | +60.2% | Q3 2026 |
| Two Sigma Investments | 162,061 | $62,673,851 | +12,762.0% | Q2 2026 |
| D. E. Shaw & Co. | 150,631 | $58,568,346 | +7.3% | Q3 2026 |
| Capital Research Global Investors | 119,078 | $34,859,671 | — | Q1 2026 |
| Millennium Management | 3,926 | $1,526,507 | -99.5% | Q3 2026 |
| T. Rowe Price | 3,876,188 | $1,507,140 | -3.5% | Q3 2026 |
| Baupost Group (Seth Klarman) | 1,275,154 | $495,805 | 0.0% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.